Abstract 252P
Background
RCC accounts for nearly 4% of all malignancies, in the Philippines, RCC ranks as the 15th most common cancer in 2018. The National Kidney and Transplant institute Cancer registry ranks RCC as the institute’s 4th most common malignancy at 10%. Studies to improve the diagnostic work up and follow up of this rare malignancy but apparently common in this institution can contribute for a better management and characterization of RCC.
Methods
This is a retrospective cohort study which included all patients who underwent nephrectomy for localized renal cell cancer from January 2017 to December 2021.
Results
There were 464 eligible patients included in this study. Clinical factors associated with recurrence of RCC upon multivariate analysis are bilateral sidedness, pT2 and beyond, WHO Grade 3-4, tumor encompassing the entire kidney, sarcomatoid and rhabdoid features, tumor necrosis, tumor thrombus, lymphovascular space invasion and positive surgical margins. Most common sites of recurrence was lungs (58.33%) followed by lymph nodes (45.83%) then bones (20.83%).
Conclusions
Presence of poor prognostic factors as well as positive lymph nodes are highly associated with local and distant RCC recurrence. A more stringent follow up with appropriate imaging may allow early intervention of metastatic diseases and possible consideration of lymph node dissection may improve recurrence free survival.
Clinical trial identification
Editorial acknowledgement
101 Health research.
Legal entity responsible for the study
The author.
Funding
National Kidney and Transplant Institute.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract